For patients with ACS undergoing DES implantation, de-escalating DAPT to P2Y12 inhibitor monotherapy is associated with lower bleeding risk.

More potent DAPT strategies and oral anticoagulation were tied to worse outcomes and should be avoided, researchers say.

Second, the irreversible P2Y12 receptor inhibition may be associated with an increased risk of hemorrhagic complications, particularly in patients requiring urgent coronary artery bypass ... including ...

Implantation of drug-eluting stents (DESs) remains central to percutaneous coronary intervention (PCI) for acute coronary syndromes (ACS) and chronic coronary syndromes (CCS). DES platforms, polymers ...

Immediately after implantation, all patients received clopidogrel 300 mg ... safe alternative to the bare-metal stent for the treatment of de novo coronary artery lesions. The results of the ...

TAMPA, Fla., Feb. 26, 2025 /PRNewswire/ -- The Patel Children's Heart Institute at St. Joseph's Children's Hospital is the first in the southeastern United States and one of only a handful of ...

TAMPA, Fla., Feb. 26, 2025 /PRNewswire/ -- The Patel Children's Heart Institute at St. Joseph's Children's Hospital is the first in the southeastern United States and one of only a handful of programs ...

Newer, more potent P2Y12 inhibitors were shown to be superior to clopidogrel in patients with ACS, including the large portion of these patients receiving coronary stents, and because the trials ...